Thomas Rønn, Author at EIR Ventures

Eir Ventures completes investment in ArgusEye to advance innovative sensor technology for real-time monitoring of bioproduction processes

by Thomas Rønn | Dec 6, 2021 | Press Releases

Eir Ventures today announced the completion of an investment in ArgusEye, a biotechnology company developing sensor solutions for real-time detection of biological systems and processes. Read the full Press Release here

Eir Ventures upscales with Investment Associate

by Thomas Rønn | Nov 23, 2021 | Press Releases

Eir Ventures welcomes Gökçe Günaydın as Investment Associate. Gökçe is joining from the pharmaceutical industry where she held global positions in Medical Affairs. She worked at the Karolinska Institute for 10 years, where she obtained her PhD. In 2021, she won the...

Eir Ventures’ first “seedling” Synklino ApS completes oversubscribed DKK 106 million series A round

by Thomas Rønn | Nov 15, 2021 | Press Releases

“It is delightful that Synklino can extend its efforts to help transplant patients. We are also glad we at Eir Ventures have enabled the progress from academic project to a financeable promising company by our participation as seed investors” says Dr Magnus Persson,...

IO Biotech, Inc. Announces Pricing of Initial Public Offering

by Thomas Rønn | Nov 5, 2021 | Press Releases, Uncategorised

Congratulations to our portfolio company IO Biotech on the successful IPO on NASDAQ. Great achievement for this pioneering company, and a milestone in the development of new pioneering treatments for Cancer patients based on the company’s T-win technology. Read the...

Galecto Announces Clinical Collaboration with Roche for Phase 2 Trial of GB1211 in Combination with Atezolizumab in First Line Non-Small-Cell Lung Cancer

by Thomas Rønn | Nov 3, 2021 | Press Releases

BOSTON, Nov. 02, 2021 (GLOBE NEWSWIRE) — Galecto, Inc. (NASDAQ: GLTO), a publicly listed biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced that it has entered into a clinical trial supply agreement with...

Eir Ventures completes investment in one-carbon Therapeutics. Magnus Persson and Alexander Mata join the board of directors, with Magnus Persson as chairman

by Thomas Rønn | Oct 26, 2021 | Press Releases

one-carbon Therapeutics is a Swedish company specialized in targeting proteins involved in one-carbon metabolism and DNA damage and repair (DDR) as a way of inducing cancer cell death. The company is developing first-in-class inhibitors targeting MTHFD2, an oncofetal...

Eir Ventures upscales with coordinator

by Thomas Rønn | Oct 21, 2021 | Press Releases

Eir Ventures has recently recruited a new coordinator, Jessica Betts who is a BSc Psychology student who is eager to graduate in June 2022. Throughout her studies, Jessica has focused on aspects such as employment relations and social dynamics in the workplace. We...

Eir Ventures completes investment in ISD Immunotech. Stephan Christgau joins board of directors

by Thomas Rønn | Oct 11, 2021 | Press Releases

ISD-Immunotech is developing a first-in-class therapy to treat the most severe Systemic lupus erythematosus (SLE) patients. The therapy works by dampening the action of an intracellular protein called STimulator of INterferon Genes (STING). STING is part of the...

Eir Ventures Co-founder Magnus Persson joins the board of Portfolio company Synklino

by Thomas Rønn | Oct 4, 2021 | Press Releases

Synklino Strengthens Board of Directors and Initiates Finance Round Synklino ApS, a biotech company developing a first-in-class breakthrough therapy to eliminate cytomegalovirus (CMV) infections in the transplant setting, today announces the appointment of Thomas...